Relationship of Initial Pancreatic Enzyme Replacement Therapy Dose With Weight Gain in Infants With Cystic Fibrosis.

ABSTRACT:

Objective

The aim of the study is to test the hypothesis of a positive relationship between initial dose of pancreatic enzyme replacement therapy (PERT) in infants with cystic fibrosis (CF) and optimal weight gain over the first 2 years of life.

Methods

Using the CF Foundation Patient Registry, we identified 502 children born in 2010 and used multivariable models to compare as our primary analysis their 2-year changes in weight-for-age z score (WAZ) and as our secondary analysis weight-for-length percentile (W/L%) by initial PERT dose. We focused on initial dose without reference to subsequent changes in treatment to avoid confounding by indication (severity).

Results

Initial PERT dose demonstrated a linear relationship to change in WAZ and W/L% at age 2 years. An ini

SUBMITTER: Schechter MS 

PROVIDER: S-EPMC6155359 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature